NeuroVive has purchased a set of cyclophilin inhibitors, technology platform assets and associated intellectual property rights from Biotica to widen its mitochondrial medicine pipeline.
The acquired portfolio of cyclophilin inhibitors belongs to Sangamides, a new class of molecules.
Sangamides leverage novel chemistry platform of polyketides and are believed to form basis for future NeuroVive products targeting cardio- and neuroprotection diseases.
NeuroVive CEO Mikael Bronnegard said the acquisition of Biotica's cyclophilin inhibitors will help NeuroVive maintain its position as cyclophilin inhibitor developers for cardio- and neuroprotection.
"These molecules are the most potent compounds for reducing mitochondrial dysfunction we have so far tested and with their novel polyketide chemistry greatly strengthen our product pipeline," Bronnegard added.
"Ownership of these Sangamides places NeuroVive in an excellent position to bring to market significantly improved and patent protected follow-on products that will further enhance the role of mitochondrial medicine across a range of diseases."